Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in Radioiodine-Refractory Differentiated Thyroid Cancer
NCT06959641Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Sep 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in differentiated thyroid cancer (DTC). Started Jun 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT06959641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959641.